Logo do repositório
 
Publicação

Levodopa and melanoma: practical recommendations for Parkinson's disease—international Parkinson and movement disorder society scientific issues committee viewpoint

2026-08-13Artigo científico Acesso aberto
Ver registo simples
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg09:Indústria, Inovação e Infraestruturas
datacite.subject.sdg17:Parcerias para a Implementação dos Objetivos
dc.contributor.authorSciacca, Giorgia
dc.contributor.authorElsayed, Inas
dc.contributor.authorPerez‐Lloret, Santiago
dc.contributor.authorOuteiro, Tiago
dc.contributor.authorUnni, Vivek K.
dc.contributor.authorKordower, Jeffery H.
dc.contributor.authorBerg, Daniela
dc.contributor.authorKalia, Lorraine V.
dc.date.accessioned2026-09-01T12:37:34Z
dc.date.available2026-09-01T12:37:34Z
dc.date.issued2026-08-13
dc.description.abstractThe potential association between Parkinson's disease (PD), melanoma, and levodopa (l-dopa) use can be a source of uncertainty and concern in clinical practice. Several etiopathological hypotheses have been proposed, including a possible role of the protein α-synuclein that, in addition to being a major component of Lewy bodies in PD, is expressed in melanocytes.1 However, a definitive mechanistic link between PD and melanoma has yet to be defined. Epidemiological data examining whether l-dopa treatment increases melanoma risk in PD patients have been contradictory, and a causal connection has not been established. Nonetheless, product monographs for l-dopa-containing medications continue to cite a history of melanoma as a contraindication and list malignant melanoma as a potential adverse effect. This discrepancy between regulatory language and the available evidence can create uncertainty for both clinicians and people with PD when initiating or continuing l-dopa therapy. The aim of this article is to provide practical recommendations for clinicians based on current evidence regarding the (1) risk of melanoma in PD independent of l-dopa treatment based on epidemiological evidence and shared pathobiological mechanisms, (2) potential risk of developing melanoma with l-dopa use in PD, and (3) safety of l-dopa treatment in PD patients with a history of melanomaeng
dc.identifier.doi10.1002/mdc3.70775
dc.identifier.eissn2330-1619
dc.identifier.issn2330-1619
dc.identifier.urihttp://hdl.handle.net/10400.1/29383
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.ispartofMovement Disorders Clinical Practice
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCancer
dc.subjectCausal
dc.subjectDermatologic
dc.subjectRisk
dc.subjectSkin
dc.titleLevodopa and melanoma: practical recommendations for Parkinson's disease—international Parkinson and movement disorder society scientific issues committee viewpointeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleMovement Disorders Clinical Practice
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameOuteiro
person.givenNameTiago
person.identifier.orcid0000-0003-1679-1727
relation.isAuthorOfPublicationc93b0b78-4cd4-40ac-adfb-32fdf38fec06
relation.isAuthorOfPublication.latestForDiscoveryc93b0b78-4cd4-40ac-adfb-32fdf38fec06

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Movement Disord Clin Pract - 2026 - Sciacca - Levodopa and Melanoma Practical Recommendations for Parkinson s Disease.pdf
Tamanho:
722.35 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FCB2-Artigos (em revistas ou actas indexadas)